Teva raises 2026 revenue guidance as Austedo, Ajovy and Uzedy lift third-quarter profit
Teva reported Q3 2026 revenue of $4.4B, down 2% YoY but above estimates. Non-GAAP EPS rose 10% to $0.86, beating forecasts, while GAAP EPS fell to $0.20. Growth in Austedo, Ajovy, and Uzedy drove profit increases.
How this was made
The 30-second read
Why it matters
A raised 2026 revenue outlook, paired with a Q3 GAAP EPS beat, can lead to upward revisions to forward revenue and earnings estimates, especially if the product drivers are sustained.
Market read
Traders can reassess Teva’s forward revenue expectations after the guidance raise and Q3 EPS beat, which may influence near-term positioning and analyst estimate revisions.
What to watch
The body excerpt does not include the specific magnitude of the 2026 guidance increase or segment details, so traders may discount the signal until full guidance numbers and management commentary are available.
Background
Teva is a large Israeli generics and specialty pharma company with key products including Austedo, Ajovy and Uzedy.
Ticker impact
Teva reported Q3 2026 revenues of $4.4B and raised 2026 revenue guidance, citing stronger performance from Austedo, Ajovy and Uzedy.
Likely upward bias as the market prices in higher 2026 revenue expectations after the guidance increase and EPS beat.
The article provides concrete Q3 results (revenue and EPS) and states 2026 revenue guidance was raised, which are direct inputs to forward estimates and valuation.
Market effects
Signals relative strength in branded specialty and migraine/HCP franchises within large generic and specialty pharma, potentially improving sentiment toward similar diversified pharma models.
Limited direct regional spillover beyond US-listed pharma sentiment.
Moderate, as Teva’s guidance change can affect global generic and specialty pharma earnings expectations.
Counterpoint
Revenue is still down year-on-year (down 2%), so the guidance raise may reflect mix or timing rather than a durable re-acceleration.
Key entities
- companyTeva
US-listed generics and specialty pharma company reporting Q3 results and raising 2026 revenue guidance.
- productAustedo
Teva product cited as contributing to improved Q3 profitability.
- productAjovy
Teva product cited as contributing to improved Q3 profitability.
- productUzedy
Teva product cited as contributing to improved Q3 profitability.
